Novo enters RNAi via liver disease deal with Dicerna

As Novo continues to remake its R&D, it is adding RNAi technology to its toolkit though a liver-focused deal with Dicerna.

The partners will use Dicerna's GalXC platform to explore more than 30 liver cell targets across liver-related cardiometabolic diseases including non-alcoholic steatohepatitis (NASH), Type II diabetes, obesity and rare diseases...